%0 Journal Article
%T Two-dose recommendation for Human Papillomavirus vaccine can be extended up to 18 years ¨C updated evidence from Indian follow-up cohort study
%A Angelika Michel
%A Bhagwan M. Nene
%A Catherine Sauvaget
%A Devasena Anantharaman
%A Eric Lucas
%A Eric Zomawia
%A Gauravi Mishra
%A Geeta Joshi
%A Julia Butt
%A Kasturi Jayant
%A M. Radhakrishna Pillai
%A Maqsood Siddiqi
%A Martin M¨¹ller
%A Martina Willhauck-Fleckenstein
%A Massimo Tommasino
%A Michael Pawlita
%A Neerja Bhatla
%A Partha Basu
%A Peter Sehr
%A Priya R. Prabhu
%A Pulikottil O. Esmy
%A Radhika Jadhav
%A Ranjit Thorat
%A Rengaswamy Sankaranarayanan
%A Richard Muwonge
%A Rintu Varghese
%A Sanjay Hingmire
%A Shachi Vashist
%A Sharmila Pimple
%A Smita Joshi
%A Subha Sankaran
%A Surendra S. Shastri
%A Sylla G. Malvi
%A Tarik Gheit
%A Thiraviam Pillai Rameshwari Ammal Kannan
%A Tim Waterboer
%A Uma Divate
%A Usha Rani Reddy Poli
%A Yogesh Verma
%A for the Indian HPV vaccine study group
%J Archive of "Papillomavirus Research".
%D 2019
%R 10.1016/j.pvr.2019.01.004
%X Earlier publication from the ongoing multi-centric study of the International Agency for Research on Cancer to evaluate less than three doses of the quadrivalent Human Papillomavirus (HPV) vaccine in India amongst unmarried girls demonstrated non-inferior total antibody titres, neutralizing antibody titres and antibody avidity in 2-dose recipients compared to 3-dose recipients at 15¨C18 years of age (Bhatla et al., 2018) [7]
%K Human papillomavirus
%K Quadrivalent vaccine
%K Two doses
%K Age 15¨C18 years
%K Immunogenicity
%K Incident infections
%K Persistent infections
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378832/